Form 4: Incyte Corp Director Paul J. Clancy Acquires 403 Shares of Common Stock

Director Paul J. Clancy acquired 403 shares of Incyte Corp common stock at $56.97 per share on March 28, 2024, and holds 15,785 shares following the transaction.

Summary

• On March 28, 2024, Paul J. Clancy, a director of Incyte Corp, acquired 403 shares of common stock.
• The shares were purchased at a price of $56.97 per share.
• The acquisition was made under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees.
• The reporting person elected to comply with Rule 10b5-1.
• Following the transaction, Clancy beneficially owns 15,785 shares of Incyte Corp common stock.
• This total includes 2,505 shares issuable pursuant to previously reported restricted stock units that have not vested.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under a pre-existing plan. The director increasing their stake is mildly positive, but the pre-planned nature reduces the impact.

Positives

• The director's acquisition of shares may signal confidence in the company's future performance.

Industry Context

Director share acquisitions are common and closely watched as they can reflect management's sentiment about the company's prospects. This transaction is part of a pre-arranged plan (Rule 10b5-1), which is a common practice to avoid insider trading concerns.

Comparison to Industry Standards

• Comparing director's stock ownership to peers like Gilead Sciences, Amgen, or Vertex Pharmaceuticals can provide context.
• Industry benchmarks for director stock ownership vary, but typically align with aligning director interests with shareholder value.
• Rule 10b5-1 plans are a standard practice among publicly traded companies to facilitate insider trading compliance.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates